The Food and Drug Administration has not approved a single psychedelic drug for medical use. Yet on Monday afternoon it opened a public hearing dedicated entirely to how psychedelic therapy should eventually reach patients.

The session ran from 12:30 to 4:30pm Eastern. It took place at the agency’s White Oak campus in Silver Spring, with a virtual option for remote attendees. Four topics filled the agenda: provider training and credentialing, patient safety, access, and data collection. Regulators normally work through these questions after a treatment clears approval, not before.

What the Hearing Will Not Discuss

The notice announcing the hearing spells out its limits clearly. FDA stated it “is not seeking comment on” the safety or effectiveness of any particular drug product. The agency also excluded the scheduling status of any substance, plus the legalisation or decriminalisation of psychedelic substances. Comments touching those subjects, the notice added, “may not be considered.”

That distinction matters. A hearing built around psychedelic treatment logistics rules out debate on whether the underlying drugs actually work. It puts the practical machinery ahead of the evidence that machinery would need.

A Policy Push Ahead of the Data

The hearing carries out Executive Order 14401. The president signed the order on 18 April. It sets a federal policy of accelerating research models and drug approvals, aiming to widen access to psychedelic therapy for serious mental illness. That same month, the agency issued national priority vouchers to several companies. These vouchers compress review timelines. Recipients include studies of psilocybin for treatment resistant depression, psilocybin for major depression, and methylone for PTSD.

FDA notes in the hearing document that a voucher does not signal safety or effectiveness. Breakthrough therapy designation carries no such weight either. Neither status substitutes for approval.

The Last Attempt Fell Short

History offers a caution here. In 2024, the agency’s Psychopharmacologic Drugs Advisory Committee voted 10 to 1 against Lykos Therapeutics’ MDMA assisted therapy for PTSD, finding its benefits did not outweigh the risks. A separate 9 to 2 vote found the company had failed to show effectiveness. Committee members pointed to selection bias and functional unblinding, the problem of patients guessing whether they received the active drug. FDA then issued a complete response letter. It stated the application “could not be approved based on data submitted to date” and asked for a further Phase 3 trial.

That rejection remains the most recent formal test any psychedelic treatment has faced before US regulators. It did not pass.

Exposure Is Already Rising Among Young People

Real world exposure has not waited for the regulatory process. Researchers at the University of Virginia School of Medicine tracked psilocybin cases among young Americans. They identified 4,055 exposures among people aged 13 to 25, reported to US poison centres between 2013 and 2022. Cases stayed flat through 2018, then began climbing in 2019. By 2022 they had more than tripled among adolescents and more than doubled among young adults. Roughly three in four cases required medical attention.

That trajectory sits uneasily alongside a hearing focused on delivery rather than underlying risk. A transcript of Monday’s proceedings will be posted to the public docket. Written comments remain open until 5 October.

The agency is preparing to spend four hours mapping out how psychedelic therapy might one day reach patients. It has yet to establish what, if anything, is actually safe or effective enough to deliver.

Source: thedrugreport